Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas

Prostate sarcoma is a rare malignancy. This paper shows the distribution of stages and outcomes for this rare malignancy.

Abstract

Background

Primary prostate sarcomas (PPS) are rare. Outcomes for this cancer have not been well characterized.

Materials and Methods

Subjects with a PPS diagnosed between 1973 and 2014 were identified in the SEER database. Subjects were stratified by disease stage and types of therapies received. Disease‐specific survival (DSS) and Overall survival (OS) was estimated by Kaplan‐Meier analysis and cohorts were compared with a univariate and multivariable Cox regression.

Results

The incidence of PPS among all prostate cancer diagnoses was 0.02%. Subjects younger than age 26 years at diagnosis represented 29% of cases, and 32% of primary prostate sarcomas were rhabdomyosarcoma histology.

Rhabdomyosarcoma Histologies

The median age at diagnosis was 9 years. Between age 0‐25 years rhabdomyosarcoma accounted for 96.4% of primary prostate sarcoma diagnoses, after age 25 rhabdomyosarcoma represented 15% of new diagnoses. The 10‐year DSS and OS for rhabdomyosarcoma was 47% and 44%.

Non‐Rhabdomyosarcoma Histologies

The median age at diagnosis was 71 years. The most common diagnoses were leiomyosarcoma (33%) and carcinosarcoma (28%). Localized, regional, or distant disease occurred in 40%, 34%, and 26% of cases. The 10‐year DSS and OS were 26% and 14%. In locally advanced cases, RT added to surgery trended toward improved DSS (P = 0.10).

Conclusions

Disease‐specific survival and OS for non‐rhabdomyosarcoma histologies appear inferior to those of rhabdomyosarcoma. The addition of RT to surgical resection may improve DSS in locally advanced non‐rhabdomyosarcoma. This is the largest report of the incidence, stage distribution, and survival for this extremely rare urologic malignancy providing valuable prognostic information.

https://ift.tt/2DASxTx